Nancy Pelosi, a name often associated with high-profile stock trades, has unveiled a major new investment.
On January 17, 2025, Pelosi reported purchasing 50 call options in Tempus AI (NASDAQ: TEM), a health technology company pioneering AI solutions for precision medicine.
The investment, worth between $50,000 and $100,000, marks the first time a politician has traded this stock, according to Finbold’s Senator Trade Tracker Tool.
Following this revelation, Tempus AI stock skyrocketed, jumping from Friday’s close of $35.15 (+1.15%) to a pre-market price of $42.56 (+21.08%) on Tuesday morning. This increase has positioned Tempus AI as a focal point for investors tracking or imitating Pelosi’s portfolio.
Tempus AI, health technology innovator
Tempus AI, which goes public in June 2024, focuses on leveraging artificial intelligence to improve precision medicine. Its flagship product, an AI-powered physician assistant, is seen as a potential disruptor in healthcare.
Despite its innovative offerings, Tempus has faced headwinds since its IPO, with shares trading roughly 12% below their initial listing price before Pelosi’s disclosure.
Last week, Tempus reported strong 2024 earnings, showing strong growth in AI-driven healthcare solutions. However, market sentiment was mixed.
Concerns arose after the sale of a prominent shareholder $33.1 million Share value, raising questions about the sustainability of the contract research division’s revenue stream.
Why does Pelosi’s trade stand out?
Pelosi’s investment has drawn particular attention because of the company’s relatively small size, with a market capitalization of less than $6 billion, and the fact that this is her first trade involving Tempus AI.
Its portfolio typically includes high-growth technology heavyweights such as Alphabet Inc. NVIDIA and Amazon, making this shift into a less established niche health technology company noteworthy.
The 21% rise in Tempus AI shares before the market reflects the significant impact Pelosi’s financial disclosures could have on market sentiment. However, the stock’s outlook remains uncertain.
While the AI assistant for doctors is well-positioned to capitalize on the growing demand for AI in healthcare, the company faces challenges in overcoming recent shareholder concerns and proving the long-term viability of its revenue streams.
Featured image via Shutterstock
